GlassScriptPhysician profile
Emily S Mcdaniel
NPI 1083321004
$3,813.56
in general payments reported to CMS, 2019-2025
44 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.00 · 2023: $1,391 · 2024: $1,284 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,638 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.56 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.78 | 2023-2025 | |
| Novo Nordisk INC | $431.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $326.97 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $255.54 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $191.20 | 2023-2025 | Rexulti |
| Janssen Biotech, INC. | $171.97 | 2025 | Tremfya |
| Bayer Healthcare Pharmaceuticals INC. | $162.06 | 2023-2024 | |
| Amgen INC. | $137.40 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.09 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $118.50 | 2023-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $115.05 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Aimmune Therapeutics, INC. | $96.16 | 2025 | Zenpep |
| Exact Sciences Corporation | $90.28 | 2023-2024 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $80.06 | 2023-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $75.21 | 2023-2025 | Trintellix, Entyvio |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $68.33 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $63.79 | 2023-2024 | Verquvo, Belsomra, Steglatro |
| Eisai INC. | $48.84 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $46.95 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $46.32 | 2023-2024 | Camzyos, Eliquis |
| Mylan Specialty L.P. | $45.50 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.59 | 2023-2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $44.08 | 2023-2024 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $39.30 | 2024-2025 | Auvelity |
| Halozyme INC | $32.23 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.37 | 2022 | |
| Ossur Americas, INC. | $25.71 | 2025 | |
| Corcept Therapeutics | $24.73 | 2024 | Korlym |
| Alnylam Pharmaceuticals INC. | $23.14 | 2024 | Givlaari |
| Lundbeck LLC | $22.67 | 2024 | Rexulti |
| Dexcom, INC. | $22.34 | 2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $20.72 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $19.92 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.02 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $18.91 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $18.14 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $17.94 | 2023 | Nuzyra |
| Olympus America INC. | $17.51 | 2025 | Evis Exera III Colonovideoscope |
| Qol Medical, LLC | $17.48 | 2025 | Sucraid |
| Echosens North America, INC. | $17.27 | 2025 | Fibroscan |
| Bausch Health US, LLC | $17.18 | 2022 | |
| Astellas Pharma US INC | $16.70 | 2023 | Veozah |
| Antares Pharma, INC. | $15.36 | 2023 | Nocdurna, Tlando, Xyosted |
| Gilead Sciences, INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.